Skip to main content

Table 3 Comparison of HDL functions

From: HDL functions and their interaction in patients with ST elevation myocardial infarction: a case control study

HDL function

Control (n = 110)

ACS baseline (n = 150)

ACS follow-up (n = 100)

Cholesterol efflux capacity (A.U.)

1.02 ± 0.16

0.88 ± 0.15***

0.94 ± 0.17###

Male

1.04 ± 0.16

0.9 ± 0.14*

0.99 ± 0.19###

Female

1.0 ± 0.14

0.87 ± 0.15*

0.93 ± 0.19

Paraoxonase activity (U/ml)

105.1 ± 56.4

69.1 ± 38.8***

81.1 ± 45.5###

Male

107.1 ± 56.2

69.5 ± 40.0*

82.4 ± 46.5###

Female

101.9 ± 57.1

65.5 ± 29.1*

72.1 ± 37.5

Arylesterase activity (U/ml)

112.0 ± 36.3

82.1 ± 27.9***

101.8 ± 30.6###

Male

113.8 ± 38.8

81.0 ± 28.1*

100.4 ± 31.0###

Female

109.4 ± 32.7

90.2 ± 26.6*

111.8 ± 26.3###

  1. Data are expressed as mean ± standard deviation. ACS Acute coronary syndrome, Paraoxonase activity represents paraoxon-hydrolyzing activity of PON1; Arylesterase activity represents phenyl acetate hydrolyzing activity of PON1. *represents significance value for comparison between control and ACS subjects. #represents significance value for comparison between ACS baseline and ACS follow-up subjects. *p < 0.05; **p < 0.01; ***p < 0.001, #p < 0.05; ##p < 0.01; ###p < 0.001